Brigden D, Whiteman P
J Infect. 1983 May;6(1 Suppl):3-9. doi: 10.1016/s0163-4453(83)94041-0.
Acyclovir (ACV) has a novel, highly selective biological activity which results in the inhibition of herpesvirus replication at concentrations 300-3000-fold lower than those that will inhibit mammalian cellular functions. Subacute and chronic studies in animals indicate that the drug is relatively non-toxic, poses no special risks to pregnancy or the foetus and does not induce detectable oncogenic or genetic changes. In man, acyclovir has a plasma half-life of approximately three hours, is widely distributed throughout the body tissues and is rapidly cleared, mainly as unchanged drug, through the kidneys. Provided that the product (Zovirax) is used according to the manufacturers' instructions, the risk of significant toxic effects is low.
阿昔洛韦（ACV）具有一种新型的、高度选择性的生物活性，它能在比抑制哺乳动物细胞功能所需浓度低300 - 3000倍的浓度下抑制疱疹病毒复制。对动物的亚急性和慢性研究表明，该药物相对无毒，对妊娠或胎儿无特殊风险，也不会引起可检测到的致癌或基因变化。在人体中，阿昔洛韦的血浆半衰期约为3小时，广泛分布于全身组织，并主要以原形药物通过肾脏迅速清除。只要按照制造商的说明使用该产品（昔洛韦），出现显著毒性作用的风险较低。
